NVSNovartis PharmaceuticalsRunning, no new patients
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Generalized Myasthenia Gravis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 146 (planned)
- Started
- Jul 31, 2024
- Main results expected
- Apr 30, 2027
- Fully finished
- May 27, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily Living (MG-ADL) total score
Measured over: Baseline to Month 6
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06517758 · record last updated 2026-08-12 · checked 2026-11-09 15:47 UTC